EU Rheumatoid Arthritis Landscape Poised for Big Changes as Rheumatologists Plan for the Adoption of Eli Lilly/Incyte’s Olumiant, Pfizer’s Xeljanz, and Regeneron/Sanofi’s Kevzara
With the recent approval of two new JAK inhibitors and the imminent introduction of additional IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management. Download Report Overview EXTON, Pa., May 4, 2017 /PRNewswire/ — Spherix Global Insights recently released data collected from 257 rheumatologists in France, Germany, Italy, Spain and the UK, revealing […]
Preference, Persistency and Positioning for Lilly’s Taltz in Psoriasis Highlight a Potential Challenge Ahead for Novartis’ Cosentyx in PsO and Psoriatic Arthritis
Spherix Global Insights has released the results of two independent surveys of dermatologists (n=100) and rheumatologists (n=100) about the evolving practice patterns in the management of psoriasis (PsO) and psoriatic arthritis (PsA). Download Report Overview: Psoriasis Download Report Overview: Psoriatic Arthritis CAMBRIDGE, MASSACHUSETTS (PRWEB) APRIL 17, 2017 Despite positive perceptions, and brand expansion from the […]
RealTime Dynamix™: Psoriatic Arthritis US Q2
The already highly dynamic US market for Psoriatic Arthritis (PsA) with the recent entrance of Celgene’s Otezla and Novartis’ Cosentyx is set to go up another level of complexity with Eli Lilly’s Taltz and AstraZeneca/Valeant’s brodalumab close to approval dates and line extensions being sought for Pfizer’s Xeljanz and Simponi Aria from Janssen. RealTime Dynamix: […]
RealTime Dynamix™: Rheumatoid Arthritis US Q2
The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of biosimilars present an […]
Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration
IL-17s stop Janssen’s Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition is looming – according to a recent study by Spherix Global Insights CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ — Spherix Global Insights has just released the results of two independent surveys of 200 rheumatologists and […]
RealTime Dynamix™: Rheumatoid Arthritis EU Q1
The EU biologics market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades the availability of biosimilars and pending introduction of several new biologics and JAK-inhibitors will alter the treatment […]
RealTime Dynamix™: Psoriatic Arthritis US Q1
The already highly dynamic US market for Psoriatic Arthritis (PsA) with the recent entrance of Celgene’s Otezla and Novartis’ Cosentyx is set to go up another level of complexity with Eli Lilly’s Taltz and AstraZeneca/Valeant’s brodalumab close to approval dates and line extensions being sought for Pfizer’s Xeljanz and Simponi Aria from Janssen. RealTime Dynamix: […]
RealTime Dynamix™: Rheumatoid Arthritis US Q1
The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of biosimilars present an […]
Will US Rheumatologists Follow in the Footsteps of Dermatologists for Adoption of Eli Lilly’s Taltz?
CAMBRIDGE, Mass., Jan. 26, 2017 /PRNewswire/ — A recent study of 100 surveyed US rheumatologists, reveals that after viewing a product profile for the likely second to market IL-17 inhibitor for PsA, 84% anticipate prescribing Lilly’s Taltz (ixekizumab), if approved. Furthermore, the vast majority of rheumatologists plan to initiate treatment within the first-year of launch. […]
Extended FDA Review for Lilly/Incyte’s Olumiant (baricitinib) in Rheumatoid Arthritis Delays Market Entry for First Major Competitor to Pfizer’s Xeljanz
And Sanofi-Regeneron’s IL-6 inhibitor, sarilumab, also getting back on track after receiving a Complete Response Letter from the FDA in October 2016. The competition to be the preferred first-line, non-TNF agent in the treatment RA is expected to be fierce in 2017, according to a new report from Spherix Global Insights Cambridge, Massachusetts. (PRWEB) January […]
